The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis

Abstract

Background: Ulcerative colitis is an inflammatory condition limited to the colon in the gastrointestinal system. Currently the most potent medications used for medical treatment of ulcerative colitis produce no response in 20%–30% of cases, in spite of a high side-effect profile. There is a need for more efficient and reliable medications. Tyrosine kinase inhibitors have shown efficacy in some inflammatory diseases and in experimental colitis models. Even though dasatinib, a tyrosine kinase inhibitor, suppresses proinflammatory cytokines in colonic tissue, there are a few case reports of haemorrhagic colitis with use of the medication. There is no study investigating the effect of dasatinib on experimental colitis. We aimed to investigate the effect of dasatinib in a colitis model induced with acetic acid in our study